S. Bouarfa, Wilma Göttgens, Suzanne A. Ligthart, Otto R. Maarsingh, Christiaan H. Vinkers, Henricus G. Ruhé, Pierre M. Bet, Jacqueline G. Hugtenburg
{"title":"Healthcare Providers' Perspectives on Antidepressant Discontinuation: A Focus Group Study","authors":"S. Bouarfa, Wilma Göttgens, Suzanne A. Ligthart, Otto R. Maarsingh, Christiaan H. Vinkers, Henricus G. Ruhé, Pierre M. Bet, Jacqueline G. Hugtenburg","doi":"10.1111/bcpt.70051","DOIUrl":null,"url":null,"abstract":"<p>Antidepressant (<span>AD</span>) discontinuation in long-term users can be challenging for both patients and healthcare providers (HCPs). Better understanding of how HCPs handle this challenge is needed to improve discontinuation care. Therefore, we identified <span>AD</span> discontinuation barriers and facilitators from the viewpoint of community pharmacists (CPs), general practitioners (GPs), psychiatrists and nurse practitioners and explored their views on their specific roles in <span>AD</span> discontinuation. Two focus group discussions involving four GPs, six pharmacists and three psychiatrists and one interview with a nurse practitioner were performed. Discussions were recorded and transcribed verbatim. Directed content analysis was performed using the theoretical domains framework. Six themes were identified: identification of patients, behaviour of HCPs regarding <span>AD</span> discontinuation, fears and emotions, context and resources, knowledge, evidence and skills and professional attitude. All HCPs stressed the importance of raising awareness for <span>AD</span> discontinuation. Barriers included fear of recurrence or discontinuation symptoms, poor collaboration between HCPs and lack of resources. Facilitators included the availability of tools and guidelines. HCPs were unaware and uncertain about each other's roles and responsibilities and showed motivation to provide guidance. This requires professional collaboration agreements and sufficient resources. Experienced CPs may contribute by identifying <span>AD</span> users and providing information/support.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"137 1","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.70051","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Basic & Clinical Pharmacology & Toxicology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/bcpt.70051","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Antidepressant (AD) discontinuation in long-term users can be challenging for both patients and healthcare providers (HCPs). Better understanding of how HCPs handle this challenge is needed to improve discontinuation care. Therefore, we identified AD discontinuation barriers and facilitators from the viewpoint of community pharmacists (CPs), general practitioners (GPs), psychiatrists and nurse practitioners and explored their views on their specific roles in AD discontinuation. Two focus group discussions involving four GPs, six pharmacists and three psychiatrists and one interview with a nurse practitioner were performed. Discussions were recorded and transcribed verbatim. Directed content analysis was performed using the theoretical domains framework. Six themes were identified: identification of patients, behaviour of HCPs regarding AD discontinuation, fears and emotions, context and resources, knowledge, evidence and skills and professional attitude. All HCPs stressed the importance of raising awareness for AD discontinuation. Barriers included fear of recurrence or discontinuation symptoms, poor collaboration between HCPs and lack of resources. Facilitators included the availability of tools and guidelines. HCPs were unaware and uncertain about each other's roles and responsibilities and showed motivation to provide guidance. This requires professional collaboration agreements and sufficient resources. Experienced CPs may contribute by identifying AD users and providing information/support.
期刊介绍:
Basic & Clinical Pharmacology and Toxicology is an independent journal, publishing original scientific research in all fields of toxicology, basic and clinical pharmacology. This includes experimental animal pharmacology and toxicology and molecular (-genetic), biochemical and cellular pharmacology and toxicology. It also includes all aspects of clinical pharmacology: pharmacokinetics, pharmacodynamics, therapeutic drug monitoring, drug/drug interactions, pharmacogenetics/-genomics, pharmacoepidemiology, pharmacovigilance, pharmacoeconomics, randomized controlled clinical trials and rational pharmacotherapy. For all compounds used in the studies, the chemical constitution and composition should be known, also for natural compounds.